Stock Events

Pacific Biosciences of California 

$1.63
284
-$0.01-0.61% Today

Statistics

Day High
1.64
Day Low
1.58
52W High
10.65
52W Low
1.16
Volume
2,720,033
Avg. Volume
9,135,403
Mkt Cap
373.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.64
-0.5
-0.36
-0.22
Expected EPS
-0.22152
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PACB. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.93B
Illumina offers sequencing and array-based solutions for genetic and genomic analysis, directly competing in the DNA sequencing market with PACB.
Bionano Genomics
BNGO
Mkt Cap42.14M
Bionano Genomics provides optical genome mapping solutions, which compete with PACB's long-read sequencing technologies.
Thermo Fisher Scientific
TMO
Mkt Cap234.95B
Thermo Fisher Scientific offers a range of sequencing and genetic analysis products, competing in the broader genomics space with PACB.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen offers sample to insight solutions including sequencing technologies that compete with PACB's offerings.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is involved in CRISPR gene editing, a field that relies on accurate DNA sequencing, where PACB's technologies are used.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the genome editing space, competing indirectly by relying on sequencing technologies similar to those offered by PACB for its gene editing projects.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is engaged in gene-based medicine, depending on sequencing technologies where PACB's long-read capabilities are beneficial.
Agenus
AGEN
Mkt Cap111.1M
Agenus is involved in immuno-oncology, a field that increasingly relies on genomic sequencing for personalized medicine, indirectly competing with PACB.
Guardant Health
GH
Mkt Cap3.15B
Guardant Health focuses on liquid biopsies and cancer diagnostics, using sequencing technologies that compete with PACB's offerings in the genomic analysis market.

Analyst Ratings

3.1$Average Price Target
The highest estimate is $7.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
55%
Hold
45%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Analytical Laboratory Instrument Manufacturing
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Show more...
CEO
Employees
796
Country
US
ISIN
US69404D1081

Listings